Genentech sues Biogen for debt over blockbuster MS drug

Published Date: 08 Mar 2023

Roche's Genentech Inc sued Biogen MA Inc in federal court in San Francisco, alleging that Biogen owed additional patent royalties from worldwide sales of its blockbuster multiple sclerosis and Crohn's disease drug, Tysabri.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Higher levels of HIF2α found to slow down aggressive childhood cancer

2.

Increased anti-tumor response and reduced side effects from immune checkpoint inhibitors.

3.

Researchers identify potential new therapeutic targets for treating T-cell lymphoma and natural killer cell tumors.

4.

Taking the "Boob Bus"; Reluctance to Grant Prior Authorization; Alcohol's Carcinogenic Potential?

5.

Significant differences in breast cancer care still exist, but surgeons can change.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot